MedTrace Logo

Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe

NCT01389310 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 249

Last updated 2014-12-23

No results posted yet for this study

Summary

The purpose of this study is to monitor adverse events in HIV-infected children \<18 years old who are exposed to Atazanavir in a real-world setting in Europe.

Conditions

  • HIV Infection

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • Belgium
  • Germany
  • Italy
  • Romania
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01389310 on ClinicalTrials.gov